Open AccessIncidence, characteristics, and treatment outcomes of mycobacterial diseases in transplant recipients
Author(s) -
Yoo JungWan,
Jo KyungWook,
Kim SungHan,
Lee SangOh,
Kim Jae Joong,
Park SuKil,
Lee JeHwan,
Han Duck Jong,
Hwang Shin,
Lee SeungGyu,
Shim Tae Sun
Publication year - 2016
Publication title -
transplant international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.998
H-Index - 82
eISSN - 1432-2277
pISSN - 0934-0874
DOI - 10.1111/tri.12752
Subject(s) - medicine , incidence (geometry) , nontuberculous mycobacteria , transplantation , tuberculosis , disease , surgery , mycobacterium , pathology , physics , optics
Summary The incidence, clinical characteristics, and treatment outcomes of tuberculosis ( TB ) and nontuberculous mycobacterial ( NTM ) disease developed after transplantation ( TPL ) in transplant recipients were investigated retrospectively. Between 1996 and 2013, 7342 solid‐organ transplantation and 1266 hematopoietic stem cell transplantation were performed at a tertiary referral center in South Korea. Among them, TB and NTM disease developed in 130 and 22 patients, respectively. The overall incidence of TB was 257.4 cases/100 000 patient‐years (95% confidence interval [ CI ], 215.1–305.7) and that of NTM disease was 42.7 cases/100 000 patient‐years (95% CI , 26.8–64.7). The median interval from organ TPL to the development of mycobacterial disease was 8.5 months (95% CI , 6.3–11.4) in recipients with TB patients and 24.2 months (95% CI , 13.5–55.7) in those with NTM , respectively. Among NTM patients, Mycobacterium avium–intracellulare complex was the most common causative organism, and nodular bronchiectatic type (77.8%) was the most frequent radiologic feature. Favorable treatment outcome was achieved in 83.7% (95% CI , 76.4–89.1) and 68.8% (95% CI , 44.4–85.8) of TB and NTM patients, respectively ( P = 0.166). In conclusion, the overall incidence of TB was higher than that of NTM disease in transplant recipients and treatment outcomes were favorable in both drug‐susceptible TB and NTM patients.